Quantitative HPV Genotyping in Screening of Anal Intraepithelial Neoplasia in HIV-positive Patients
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Diagnostic Test: HPV genotyping
- Registration Number
- NCT03742375
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Brief Summary
The pathophysiology from anal HPV infection to Anal Intraepithelial Neoplasia is less well understood than cervical HPV infection. In cervical screening programs it is well accepted that the sole presence of a high-risk HPV strain (irrespective of number of viral particles) is sufficient to justify further investigation and treatment. The investigators hypothesize that in anal HPV infection not only the presence but the extent of HPV infection (single genotype viral load) or combination of different HPV genotypes (cumulative viral load) is of importance in determining the risk of anal dysplasia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Male
- Target Recruitment
- 24
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description HPV genotyping HPV genotyping -
- Primary Outcome Measures
Name Time Method Incidence of HPV subtypes in HIV-positive patients 1 minute Retrieval of 1 anal swab before performing HRA to determine the HPV subtypes at that particular moment
- Secondary Outcome Measures
Name Time Method Correlation between high-resolution anoscopy findings and quantitative HPV genotyping 30 minutes up to 10 days Performing HRA (30 minutes) with or without biopsies, results biopsies up to 10 days
Trial Locations
- Locations (1)
University Hospitals Leuven
🇧🇪Leuven, Belgium